SRI International Biosciences Executives to Present Seminar on Commercialization of Drug Discovery
MENLO PARK, Calif. -- September 8, 2006 -- SRI International, an independent nonprofit research and development organization, today announced that it will host a luncheon seminar at BioJapan 2006 in Osaka, Japan. Walter H. Moos, Ph.D., vice president of SRI International's Biosciences Division will present a talk titled "Marrying Academic Discoveries with Industrial Strength Drug Development" on Thursday, September 14 in room 1202 of the Osaka International Convention Center (Grand Cube Osaka) at 12:00 pm.
Nathan Collins, Ph.D., executive director of SRI’s Biosciences Division will make introductory remarks, and Osamu Karatsu, Ph.D., executive director of SRI Japan will moderate the discussion. In his presentation, Dr. Moos will discuss SRI's business model as a drug discovery organization that is able to perform academic research like a university, drug discovery like a biotech company, and full-service non-clinical development like a contract research organization. A combination of government-funded biological and chemical research and industry partnerships enable SRI to develop high-quality drug candidates for clinical development.
SRI's approach to drug discovery and innovation has led to several drugs and related products that are currently on the market, and a strong pipeline of new drugs that are in various phases of clinical trials. SRI is seeking new opportunities for alliances that will advance drug discovery.
Dr. Moos is an industry leader with nearly 25 years of pharmaceutical and biotechnology experience, and has made significant contributions to all stages of drug discovery and development.
For more information or to register for the seminar, please contact: biosciences@sri.com
SRI representatives will also be available to discuss SRI innovations and drug discovery programs in booth # B018 on the 3rd floor of the Osaka International Convention Center.
###
About SRI's Biosciences Division
The SRI Biosciences Division is a unique organization of approximately 200 people, with all of the resources necessary to take chemical and biological research programs from "idea to IND"™ -- from initial discovery to investigational new drug applications to start human clinical trials. The Biosciences Division performs basic research on disease mechanisms like an academic institution; drug discovery and the development of biologics like a biotechnology or pharmaceutical company; and full-service preclinical contract research and development and pharmaceutical sciences like a CRO (contract research organization).
To date, SRI has developed nine drugs internally that have entered clinical trials, with several more currently undergoing preclinical evaluation. Marketed examples of these drugs include bexarotene and halofantrine. Additionally, working with government and industry partners, SRI has helped advance more than 100 drugs into clinical trials, and more than 30 drugs onto the market. Through collaborations with other divisions at SRI, Biosciences is also working at the interfaces of science to create technical platforms for the next generation of drug discovery and development in areas such as drug delivery, real-time diagnostics and systems biology.
About SRI International
Silicon Valley-based SRI International (www.sri.com) is one of the world’s leading independent research and technology development organizations. Founded as Stanford Research Institute in 1946, SRI has been meeting the strategic needs of clients for 60 years. The nonprofit research institute performs client-sponsored research and development for government agencies, commercial businesses, and private foundations. In addition to conducting contract R&D, SRI licenses its technologies, forms strategic partnerships, and creates spin-off companies.
###
